195 related articles for article (PubMed ID: 9445131)
21. [Relationship between malignant transformation of ovarian mucinous cystadenoma and intestinal epithelial metaplasia].
Zhong CQ
Zhonghua Bing Li Xue Za Zhi; 1989 Jun; 18(2):134-6. PubMed ID: 2555075
[TBL] [Abstract][Full Text] [Related]
22. Telomerase activity in benign and malignant epithelial ovarian tumors.
Wan M; Li WZ; Duggan BD; Felix JC; Zhao Y; Dubeau L
J Natl Cancer Inst; 1997 Mar; 89(6):437-41. PubMed ID: 9091645
[TBL] [Abstract][Full Text] [Related]
23. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
[TBL] [Abstract][Full Text] [Related]
24. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
25. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Lu JJ; Zheng Y; Kang X; Yuan JM; Lauchlan SC; Pike MC; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):158-68. PubMed ID: 11063638
[TBL] [Abstract][Full Text] [Related]
26. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
[TBL] [Abstract][Full Text] [Related]
27. Lectin histochemistry in mucinous and serous ovarian neoplasms.
Sasano H; Saito Y; Nagura H; Kudo R; Rojas M; Silverberg SG
Int J Gynecol Pathol; 1991; 10(3):252-9. PubMed ID: 1655666
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
29. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Anglesio MS; Arnold JM; George J; Tinker AV; Tothill R; Waddell N; Simms L; Locandro B; Fereday S; Traficante N; Russell P; Sharma R; Birrer MJ; ; deFazio A; Chenevix-Trench G; Bowtell DD
Mol Cancer Res; 2008 Nov; 6(11):1678-90. PubMed ID: 19010816
[TBL] [Abstract][Full Text] [Related]
30. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
31. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
[TBL] [Abstract][Full Text] [Related]
32. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix.
Zauber P; Berman E; Marotta S; Sabbath-Solitare M; Bishop T
Scand J Gastroenterol; 2011 Jul; 46(7-8):869-74. PubMed ID: 21443421
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D; Vlodavsky E; Simon E; Ben-Izhak O
Pathol Int; 2013 Dec; 63(12):611-4. PubMed ID: 24422958
[TBL] [Abstract][Full Text] [Related]
34. Mutation of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas.
Suzuki M; Saito S; Saga Y; Ohwada M; Sato I
Cancer Genet Cytogenet; 2000 Apr; 118(2):132-5. PubMed ID: 10748293
[TBL] [Abstract][Full Text] [Related]
35. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
36. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
Desouki MM; Khabele D; Crispens MA; Fadare O
Int J Gynecol Pathol; 2015 Jan; 34(1):19-24. PubMed ID: 25473748
[TBL] [Abstract][Full Text] [Related]
37. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations.
Cuatrecasas M; Matias-Guiu X; Prat J
Am J Surg Pathol; 1996 Jun; 20(6):739-46. PubMed ID: 8651354
[TBL] [Abstract][Full Text] [Related]
38. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
[TBL] [Abstract][Full Text] [Related]
39. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas.
Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L
Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906
[TBL] [Abstract][Full Text] [Related]
40. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
